脳梗塞急性期の患者血清を用いた脳血管平滑筋細胞増殖に対する ラジカル·スカベンジャー,エダラボンの効果とアムロジピンの Pleiotropic 作用による影響

書誌事項

タイトル別名
  • Alterations of Antiproliferative Effects of Serum Obtained from Patients with Acute Cerebral Infarction Treated with a Radical Scavenger, Edaravone, with or without Amlodipine Using an <i>in vitro</i> Cultured Basilar Artery Smooth Muscle Cells
  • 脳梗塞急性期の患者血清を用いた脳血管平滑筋細胞増殖に対するラジカル・スカベンジャー,エダラボンの効果とアムロジピンのPleiotropic作用による影響
  • ノウコウソク キュウセイキ ノ カンジャ ケッセイ オ モチイタ ノウケッカン ヘイカツキン サイボウ ゾウショク ニ タイスル ラジカル スカベンジャー エダラボン ノ コウカ ト アムロジピン ノ Pleiotropic サヨウ ニ ヨル エイキョウ

この論文をさがす

抄録

  The guinea-pig basilar artery smooth muscle cell (GBa-SM3) culture system in the Dulbecco's modified Eagle's medium for 3 days serves as a useful in vitro model for assessing antiproliferative effects of various therapeutic agents on vessels. With use of this system we studied whether human serum obtained from patients with acute cerebral infarction (n=16) would have a proliferative effect on vessels and whether an administration of a free radical scavenger, edaravone, with or without amlodipine would elicit antiproliferative effects. The control serum was obtained from 3 healthy human subjects. Time courses of the cell growth and survival were measured colorimetrically by the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) test. The stimulatory effect on the proliferation of GBa-SM3 cells of patients' serum obtained immediately after infarction was significantly (p<0.05) greater than those obtained from the same patients after the treatment of edaravone for 2 weeks. In addition, the serum obtained from the patients treated by edaravone and amlodipine (n=7) showed a significantly (p<0.05) greater antiproliferative effect than that obtained from those treated by edaravone (n=9). In conclusion, edaravone may have a clinically beneficial antiproliferative effect on vascular smooth muscle cells. Co-administration of amlodipine, possessing an antioxidative calcium channel blocker, with edaravone may be a promising combination to patients with acute cerebral infarction. Further controlled clinical trials with a large number of patients should be warranted.

収録刊行物

  • 薬学雑誌

    薬学雑誌 124 (1), 25-29, 2004-01-01

    公益社団法人 日本薬学会

被引用文献 (2)*注記

もっと見る

参考文献 (29)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ